Innate Immune Response in Cardiac Healing and Rejuvenation
Innate Immune Response in Cardiac Healing and Rejuvenation
批准号:
10625955
负责人:
Jeffery D Molkentin
金额:
$37.71万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-04-05 至 2028-03-31
关键词:
AcuteAdoptedAdultApoptosisAreaAtherosclerosisBacteriaBasic ScienceBioinformaticsBiologyBlood VesselsCardiacCardiac MyocytesCardiovascular systemCell TherapyCell secretionCellsCicatrixClinical DataClinical TrialsCollaborationsCompensationComplement ActivationDNADataDendritic CellsDiseaseEndothelial CellsEventFibroblastsGenesGoalsGrowthHeartHeart InjuriesHeart failureHumanImmuneImmune responseImmune signalingInfarctionInfectionInflammasomeInflammationInflammatoryInflammatory ResponseInfusion proceduresInjection of therapeutic agentInjectionsInjuryInnate Immune ResponseLiteratureLongevityMacrophageMediatingMusMuscle CellsMyocardial InfarctionNatural regenerationNatureNeurosecretory SystemsOutcomePathway interactionsPatientsPattern recognition receptorProductionProteinsRNARegulationRejuvenationReportingReproducibilityResearchRodent ModelSignal PathwaySignal TransductionStimulator of Interferon GenesSting InjuryStructureTherapeuticTherapy trialTissue ExpansionTissuesToll-like receptorsUncertaintyVirusWestern WorldWorkadult stem cellcardiac regenerationcell typefungusgenetic manipulationhealingimprovedinjuredinnate immune mechanismsischemic injurymouse geneticsneutrophilnovelnovel therapeuticsparacrinephysical propertyprotective effectrepairedresponseresponse to injurystem cell therapystem cellstransdifferentiation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Myocardial infarction (MI) due to underlying atherosclerosis is the leading disease
sequela that precipitates heart failure in the Western world. Our ability to treat these
patients and their heart failure has not progressed beyond a mild 20-30% extension in
life span realized some 3 decades ago with neuroendocrine-based management. New
therapeutic avenues are needed, the most dramatic of which would be directly
generating new cardiomyocyte to regenerate the damaged area of heart tissue.
Previous attempts to regenerate the heart through new myocyte production have not
been successful despite more than 15 years of research using adult progenitor cells.
However, studies with cardiac progenitor cells in rodent models did show a functional
benefit to the MI-injured heart, and we and others have identified a novel mechanism of
benefit whereby injected progenitor cells had a rejuvenating effect through refinement of
the immune response. Indeed, we have shown that cell therapy injections can optimize
healing, reduce infarct area expansion and augment scar borderzone physical properties
(Vagnozzi et al., 2020, Nature). These beneficial effects were mediated through
selective macrophage subtype activity in the heart, underscoring the importance of the
immune response in infarct healing and compensation. Here we propose the hypothesis
that selective innate immune response signaling pathways, and macrophage subtype
polarization can be exploited to further heal MI injury. Our more specific hypothesis is
that MI injury or cell therapy has an underlying protective component through cGAS-
Sting in both cardiomyocytes and macrophages, and this can be therapeutically
exploited to polarize the immune response for better healing. The specific aims are:
AIM #1, To use mouse genetics to identify the specific immune cell-types in the heart
that mediate cell therapy-based cardiac rejuvenation post-MI injury. AIM #2, To examine
the mechanism of innate immune signaling in the heart through cGAS-Sting. AIM #3, To
investigate the mechanisms whereby cell therapy rejuvenates the post-MI injured heart.
Such studies will be critical for examining how innate immune signaling at the level of
macrophages impacts the heart during an inflammatory injury response or due to cell
therapy with the goal of modifying this response to benefit healing in patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cell therapy regulates cardiac healing through innate immune response
-
批准号:10561163
-
项目类别:
-
资助金额:$3.65万
-
财政年份:2023
-
负责人:Jeffery D Molkentin
-
依托单位:
Mouse Cardiac Physiology and Surgical Core (Core C)
-
批准号:10625950
-
项目类别:
-
资助金额:$12.04万
-
财政年份:2023
-
负责人:Jeffery D Molkentin
-
依托单位:
Thrombospondin1-regulated atrophy in the heart
-
批准号:10578361
-
项目类别:
-
资助金额:$60.36万
-
财政年份:2022
-
负责人:Jeffery D Molkentin
-
依托单位:
Dissecting the role of the cardiac fibroblast in hypertrophy.
-
批准号:10667595
-
项目类别:
-
资助金额:$60.9万
-
财政年份:2022
-
负责人:Jeffery D Molkentin
-
依托单位:
Innate immune response signaling in cardiac injury healing
-
批准号:10350020
-
项目类别:
-
资助金额:$60.52万
-
财政年份:2022
-
负责人:Jeffery D Molkentin
-
依托单位:
Innate immune response signaling in cardiac injury healing
-
批准号:10544189
-
项目类别:
-
资助金额:$60.52万
-
财政年份:2022
-
负责人:Jeffery D Molkentin
-
依托单位:
Dissecting the role of the cardiac fibroblast in hypertrophy.
-
批准号:10514028
-
项目类别:
-
资助金额:$60.9万
-
财政年份:2022
-
负责人:Jeffery D Molkentin
-
依托单位:
In vivo role of the fibroblast in muscular dystrophy
-
批准号:10377963
-
项目类别:
-
资助金额:$34.63万
-
财政年份:2018
-
负责人:Jeffery D Molkentin
-
依托单位:
Cardiac fibroblasts in postnatal development and adult injury response
-
批准号:10217231
-
项目类别:
-
资助金额:$68.72万
-
财政年份:2018
-
负责人:Jeffery D Molkentin
-
依托单位:
Cardiac Fibroblasts in Postnatal Development and Adult Injury Response
-
批准号:10640493
-
项目类别:
-
资助金额:$80.25万
-
财政年份:2018
-
负责人:Jeffery D Molkentin
-
依托单位:
In vivo role of the fibroblast in muscular dystrophy
-
批准号:9888312
-
项目类别:
-
资助金额:$34.98万
-
财政年份:2018
-
负责人:Jeffery D Molkentin
-
依托单位:
Thrombospondin 4 regulates adaptive ER stress response
-
批准号:8600986
-
项目类别:
-
资助金额:$46.72万
-
财政年份:2011
-
负责人:Jeffery D Molkentin
-
依托单位:
Thrombospondin 4 regulates adaptive ER stress response
-
批准号:9197329
-
项目类别:
-
资助金额:$43.67万
-
财政年份:2011
-
负责人:Jeffery D Molkentin
-
依托单位:
Thrombospondin 4 regulates adaptive ER stress response
-
批准号:8027876
-
项目类别:
-
资助金额:$48.11万
-
财政年份:2011
-
负责人:Jeffery D Molkentin
-
依托单位:
Thrombospondin 4 regulates adaptive ER stress response
-
批准号:8209251
-
项目类别:
-
资助金额:$48.03万
-
财政年份:2011
-
负责人:Jeffery D Molkentin
-
依托单位:
Thrombospondin 4 regulates adaptive ER stress response
-
批准号:8403969
-
项目类别:
-
资助金额:$45.56万
-
财政年份:2011
-
负责人:Jeffery D Molkentin
-
依托单位:
Thrombospondin 4 Regulates Adaptive ER Stress Response
-
批准号:10337332
-
项目类别:
-
资助金额:$45.85万
-
财政年份:2011
-
负责人:Jeffery D Molkentin
-
依托单位:
The ERK-MAPK signaling branch in the heart
-
批准号:8208659
-
项目类别:
-
资助金额:$29.38万
-
财政年份:2011
-
负责人:Jeffery D Molkentin
-
依托单位:
Thrombospondin 4 regulates adaptive ER stress response
-
批准号:8965510
-
项目类别:
-
资助金额:$48.44万
-
财政年份:2011
-
负责人:Jeffery D Molkentin
-
依托单位:
The ERK-MAPK signaling branch in the heart
-
批准号:8148044
-
项目类别:
-
资助金额:$29.09万
-
财政年份:2010
-
负责人:Jeffery D Molkentin
-
依托单位:
海外基金